Capstone Therapeutics Corp.
| OTC Markets: CAPS
Capstone Therapeutics Corp. is a biotechnology company that develops a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The company is focused on development and commercialization of two product platforms: AZX100 and Apo E Mimetic Peptide, AEM-28 and its analogs. The AZX100 is a novel synthetic 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. The Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. The AEM-28 is a 28 amino acid mimetic of Apo E that contains a domain that anchors into a lipoprotein surface while also providing the Apo E binding domain that is removed by heparin sulfate receptors in the liver. The AEM-28 as an Apo E mimetic has the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. The company was founded in July 1987 and is headquartered in Tempe, AZ.